Review article: Gastro-oesophageal reflux disease as a functional gastrointestinal disorder

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 7, 2004, Pages 50-55

  Kahrilas, P J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; BACLOFEN; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; GLUTAMIC ACID; IMIPRAMINE; NEUROTRANSMITTER; PEPSIN A; PROTON PUMP INHIBITOR; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; STOMACH SECRETION INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS MANOMETRY; ESOPHAGUS MUCOSA; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEARTBURN; HISTOPATHOLOGY; HUMAN; HYPERALGESIA; LOWER ESOPHAGUS SPHINCTER; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PH MEASUREMENT; PRIORITY JOURNAL; REMISSION; SEDATION; SIDE EFFECT; STOMACH ACID; STOMACH EMPTYING; SYMPTOM;

EID: 10644278754     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02185.x     Document Type: Conference Paper

References (29)

1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999; 44: S1-16.
2. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA. Functional esophageal disorders. Gut 1999; 45(Suppl. II): II31-6.
3. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
4. Lundell LR, Dent J, Bennett DH, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
5. Ismail-Beigi F, Horton PF, Pope CE II. Histological consequences of gastroesophageal reflux in the distal esophagus in man. Gastroenterology 1970; 58: 163-74.
6. Vieth M, Haringsma J, Delarive J, et al. Red streaks in the oesophagus in patients with reflux disease: is there a histomorphological correlate? Scand J Gastroenterol 2001; 36: 1123-7.
7. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular space: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200-5.
8. Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparison of results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003; 18: 525-32.
9. Vitale GC, Cheadle WG, Sadek S, Michel ME, Cushieri A. Computerized 24-hour ambulatory esophageal pH monitoring and esophagogastroduodenoscopy in reflux patients. Ann Surg 1984; 20: 724-8.
10. Masclee AAM, De Best ACAM, De Graaf R, Cluysenaer OJJ, Jansen JBMJ. Ambulatory 24-hour pH-metry in the diagnosis of gastroesophagal reflux disease. Scand J Gastroenterol 1990; 25: 225-30.
11. Mattioli S, Pilotti V, Spangaro M, et al. Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux disease. Dig Dis Sci 1989; 34: 71-8.
12. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 740-9.
13. Wiener GJ, Richter JE, Copper JB, et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988; 83: 358-61.
14. Breumelhof R, Smout AJPM. The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 1991; 86: 160-4.
15. Weusten BLAM, Roelofs JMM, Akkermans LMA, et al. The symptom association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994; 107: 1741-5.
16. Shi G, Bruley des Varannes S, Scarpignato C, et al. Reflux-related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.
17. Trimble KC, Douglas S, Pryde A, et al. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40: 1098-104.
18. Watson RGP, Tham TCK, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the 'sensitive oesophagus'. Gut 1997; 40: 587-90.
19. Drossman DA. Importance of the psyche in heartburn and dyspepsia. Aliment Pharmacol Ther 1997: 11(Suppl. 2): 57-67.
20. Johnston BT, Lewis SA, Love AHG. Psychological factors in gastro-oesophageal reflux disease. Gut 1995; 36: 481-2.
21. Trimble KC, Douglas S, Pryde A, et al. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37: 7-12.
22. Zagorodnyuk VP, Chen BN, Brookes SJ. Intraganglionic laminar endings are mechano-transduction sites of vagal tension receptors in the guinea-pig stomach. J Physiol 2001; 534: 255-68.
23. Zagorodnyuk VP, Chen BN, Costa M, Brookes SJ. 4-Aminopyridine- and dendrotoxin-sensitive potassium channels influence excitability of vagal mechano-sensitive endings in guinea-pig oesophagus. Br J Pharmacol 2002; 137: 1195-206.
24. Ciggaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 53: 464-70.
25. Kahrilas PJ, Quigley EMM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 1503-9.
26. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
27. Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: double-blind, placebo-controlled trial. Gastroenterology 1986; 92: 1027-36.
28. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42: 807-13.
29. Gorelick AB, Koshy SS, Hooper FG, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275: G460-6.